Clinical trials: GLP-1
Obesity; Chronic Kidney Disease; Albuminuria
Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate whether starting finerenone together with semaglutide provides an additional reduction in urinary albumin-to-creatinine ratio…
- Trial name
- NCT07849348
- Testing
- Finerenone, Semaglutide
- Volunteers
- 266 people
- Sponsor
- Peking University People's Hospital
Obesity, Chronic Kidney Diseases
Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease
The goal of this clinical trial is to exploring the changes in 24-hour urinary protein and renal function in obese patients with kidney disease after the application of sodium glucose cotransporter 2 inhibitors (SGLT2i) and…
- Trial name
- NCT06344247
- Testing
- RAS inhibitors：Losartan®️/Valsartan®️, dapagliflozin：Forxiga®️, simagliptin：Forxiga®️
- Where
- China
- Volunteers
- 48 people
- Sponsor
- RenJi Hospital
Obesity
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the treatment of subjects who are overweight or obese.
- Trial name
- NCT03671733
- Testing
- Liraglutide, Exenatide, Exenatide Microspheres for Injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xiangya Hospital of Central South University
Bariatric Surgery (Gastric Bypass)
Can Postprandial Reactive Hypoglycaemia be Reduced in Patients After Roux-en-Y Gastric Bypass With a Low Carbohydrate Diet?
Roux-en-Y gastric bypass (RYGB) accelerates nutrient delivery to the small intestine causing higher peak blood glucose concentration early after meal intake.
- Trial name
- NCT02665715
- Testing
- Low carbohydrate meals, Standard carbohydrate meals
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Amirsalar Samkani
Gastrointestinal Symptoms, Weight Loss
A Trial to Assess Gastrointestinal Responses to Dietary Fibers in Adults Using Weight Loss Medications
The objective of this study is to assess self-reported gastrointestinal (GI) responses to three snack bars containing fiber/fiber blends vs. a control snack bar for 7 days each in adults using GLP-1 agonists.
- Conditions
- Gastrointestinal Symptoms, Weight Loss, GLP-1
- Trial name
- NCT07012317
- Testing
- High Fiber Bar with Inulin, High Fiber bar with Fiber Blend, High Fiber Bar with Resistant Starch type 4
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Midwest Center for Metabolic and Cardiovascular Research
Myocardial Infarction
GLP-1 on Non-ST-Segment Elevation Myocardial Infarction
The investigators planned to evaluate the effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction (NSTEMI).
- Trial name
- NCT02577848
- Testing
- GLP-1
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese PLA General Hospital
Type 1 Diabetes
Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2
In previous studies, investigators have studied if a pre-meal insulin bolus based on estimated carbohydrate meal size would alleviate the burden of carbohydrate counting without a significant degradation in postprandial glucose…
- Trial name
- NCT02798250
- Testing
- Dual-hormone closed-loop, Insulin, Glucagon
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Insulin Secretion
Incretin Action in Physiology and Diabetes
This project is designed to advance understanding of the incretin effect in health and disease. This system of gut-islet linkage is essential for normal glucose tolerance, impaired in T2DM, and amenable to therapeutic…
- Trial name
- NCT02550548
- Testing
- GIP infusion, GLP-1 infusion, Ex-9 infusion
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- David D'Alessio, M.D.
Kidney Diseases
The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.
This study will investigating the effects of glucagon on renal blood flow in humans using MRI technology. Glucagon, a hormone produced by the pancreas, plays a key role in regulating blood sugar levels.
- Trial name
- NCT06872060
- Testing
- Glucagon, Glucagon+Exendin9-39, Sodium chloride
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Glucose Metabolism Disorders
The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D
Delineation of the role of glucagon-like peptide-1 receptor signalling in the glucose-lowering effect of metformin during meal ingestion in patients with type 2 diabetes.
- Trial name
- NCT03246451
- Testing
- Metformin, Saline, Exendin (9-39)
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Prostate Cancer
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
- Trial name
- GAINPCCONTROL (NCT06908694)
- Testing
- Semaglutide Pen Injector
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Hamilton Health Sciences Corporation
Overweight , Obesity
TRPTI Metabolic and GLP-1 Pharmacodynamic Study
The goal of this clinical trial is to assess whether TRPTI™ supplementation affects GLP-1 and related metabolic markers in generally healthy adults who are overweight or obese (BMI 25.0-34.9 kg/m², aged 30 years and older).
- Trial name
- NCT07850466
- Testing
- TRPTI
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes
This study will investigate how the body processes nasal glucagon (NG) and the effect of nasal glucagon on the body. The study is expected to last about 50 days for each participant.
- Trial name
- NCT02806973
- Testing
- Nasal Glucagon
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Hypoglycemia
Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes
Type 1 diabetes (T1D) results from destruction of insulin producing beta cells by the body's own immune system (autoimmunity) causing an individual to lose the ability to make enough insulin to control their blood sugar levels…
- Trial name
- MUGGLE (NCT05616273)
- Testing
- Mixed Meal Tolerance Test (MMTT), Arginine Stimulation Test (AST), Home Finger Prick Sample
- Where
- United Kingdom
- Volunteers
- 62 people
- Sponsor
- University of Exeter
Hypoglycemia, Diabetes Mellitus, Type 1
The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes
Objective: Because many people with type 1 diabetes drink ethanol and because glucagon is used to treat mild hypoglycaemia, it is essential to determine whether ethanol will impair the effectiveness of glucagon to increase…
- Trial name
- ALCO1 (NCT02881060)
- Testing
- Alcohol
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Hvidovre University Hospital
Gastric Bypass Surgery, Obesity
Mechanisms of Diabetes Control After Weight Loss Surgery
Obesity and type 2 diabetes (T2DM) are increasing in the US. One third of patients seeking bariatric surgery have T2DM. Although all surgeries result in significant weight loss and often 'cure' the T2DM, the rapid onset and the…
- Trial name
- NCT00571220
- Testing
- gastric bypass surgery, Diet induced weight loss
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Diabetes Mellitus, Type 2
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body), and pharmacodynamics (the effect of the investigated drug on the body)…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01686945
- Testing
- semaglutide
- Where
- Germany
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Diabetes Mellitus, Type 1
Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care
A closed-loop insulin system, also referred to as the "artificial pancreas" (AP), is made up of an insulin pump, a continuous glucose monitor, and an application communicating between the two to adjust insulin administration…
- Trial name
- SEMA-AP (NCT05205928)
- Testing
- Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Obesity
IG vs ID Bitter Administration
We want to investigate whether bitter compounds, denatonium benzoate and quinine hydrochloride, have a distinct effect on gastrointestinal hormone release after infusion into the stomach or duodenum.
- Trial name
- IG vs ID (NCT03985865)
- Testing
- Intragastric quinine hydrochloride, Intragastric denatonium benzoate, Intraduodenal quinine hydrochloride
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Diabetes Mellitus
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in patients with type 1 diabetes…
- Trial name
- NCT00732602
- Testing
- GIP-infusion, Sodium-chloride, GLP-2 infusion
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.